Thiazolidinediones (TZDs) are a class of medicines commonly used alongside diet and exercise as therapeutic agents for the treatment of patients with type 2 diabetes mellitus, a disease in which defects in both peripheral insulin resistance and pancreatic beta cell insulin secretion coexist (Arcidiacono et al., 2015). The gene discussed is INS; the disease is type 2 diabetes mellitus.